New Hope Therapeutics

HOPE Therapeutics is a healthcare delivery company and wholly owned subsidiary of NRx Pharmaceuticals focused on building a multi-site interventional psychiatry network. The company provides commercial mental health services centered on neuroplastic therapies including transcranial magnetic stimulation, IV ketamine, and Spravato, alongside psychotherapy and psychiatry. HOPE is targeting severe and difficult-to-treat CNS-related conditions such as depression, suicidality, PTSD, anxiety, OCD, and related disorders. In addition to operating clinics directly, the company has pursued an acquisition-led expansion strategy, including Dura Medical and announced transactions involving NeuroSpa and Kadima. HOPE also appears tied to NRx's broader CNS strategy around ketamine-based therapies and digital therapeutic augmentation.